Physician profile
Daniel A Polansky
NPI 1578561593
$16,890.67
in general payments reported to CMS, 2019-2025
55 companies · $3,352 in 2025
The $3,352 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,653 · 2020: $1,830 · 2021: $2,759 · 2022: $2,251 · 2023: $2,529 · 2024: $2,516 · 2025: $3,352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,314 · Education: $83.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,314.13 |
| Education | $83.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,461.78 | 2019-2025 | |
| Amgen INC. | $3,330.01 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Ucb, INC. | $921.46 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $876.64 | 2019-2025 | Tremfya, Simponi, Stelara |
| Janssen Pharmaceuticals, INC | $786.42 | 2019-2025 | Xarelto, Tremfya |
| Lilly USA, LLC | $769.22 | 2019-2025 | Mounjaro, Emgality, Jardiance |
| Mallinckrodt Hospital Products INC. | $655.65 | 2020-2024 | Acthar |
| Novo Nordisk INC | $582.05 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $480.30 | 2020-2025 | Ofev, Synjardy, Cyltezo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $404.52 | 2019-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $383.33 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $358.61 | 2024-2025 | |
| Pfizer INC. | $330.43 | 2019-2025 | |
| Radius Health, INC. | $193.38 | 2020-2025 | Tymlos |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $185.73 | 2025 | Caplyta |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Polansky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.